Literature DB >> 20373127

Electronic compliance monitoring of topical treatment after ophthalmic surgery.

Manuel Marcel Hermann1, Can Ustündag, Michael Diestelhorst.   

Abstract

The success of many medical treatments is built on compliance. Electronic monitoring is the most accurate tool to quantify compliance by measuring adherence. In order to assess the efficiency of a recently introduced miniature monitoring device for eye drop application, we evaluated adherence in ophthalmic patients undergoing post-operative short-term topical treatment. This pilot study enrolled 30 outpatients (mean age 61.8 +/- 18.5 years) after cataract (n = 24) and glaucoma filtration surgery (n = 6) applying fixed-combination eye drops containing prednisolone and gentamicin five times daily for 2 weeks. Patients received eye drops in conventional bottles each equipped with a miniature monitoring device recording events of application. Two patients failed to bring back the monitoring device; therefore data collected from only 28 patients could be examined. Data showed highly variable results with a mean dose compliance of 50.2%. Dose compliance was below 25% in approximately one out of five patients. Four cataract patients, but no glaucoma patient, discontinued therapy prematurely. The observed mean dosage interval was calculated for each patient and ranged 4.6-19.7 h. Thirty percent of analysed dosage intervals exceeded 12.0 h. Different patterns of compliance behaviour-like early non-persistence, drug holiday and low treatment frequency could be identified and illustrated using electronic data. Age or gender did not significantly influence compliance rates. Our pilot study demonstrates successful electronic compliance monitoring using a technology capable of continuous data recording over weeks of treatment. The low compliance rate for a relevant part of the patients demonstrates the necessity to study and improve compliance in ophthalmology. In future, new application methods and electronic application devices may improve treatment response in eye care.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20373127     DOI: 10.1007/s10792-010-9362-3

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  20 in total

1.  Microprocessor controlled compliance monitor for eye drop medication.

Authors:  M M Hermann; M Diestelhorst
Journal:  Br J Ophthalmol       Date:  2006-03-15       Impact factor: 4.638

2.  Compliance with topical timolol treatment.

Authors:  M A Kass; M Gordon; R E Morley; D W Meltzer; J J Goldberg
Journal:  Am J Ophthalmol       Date:  1987-02-15       Impact factor: 5.258

Review 3.  Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review.

Authors:  Christine M G Olthoff; Jan S A G Schouten; Bart W van de Borne; Carroll A B Webers
Journal:  Ophthalmology       Date:  2005-06       Impact factor: 12.079

4.  Patient-reported behavior and problems in using glaucoma medications.

Authors:  Betsy Sleath; Alan L Robin; David Covert; John E Byrd; Gail Tudor; Bonnie Svarstad
Journal:  Ophthalmology       Date:  2006-02-03       Impact factor: 12.079

Review 5.  Developments in dosing aids and adherence devices for glaucoma therapy: current and future perspectives.

Authors:  Malik Y Kahook
Journal:  Expert Rev Med Devices       Date:  2007-03       Impact factor: 3.166

6.  Persistence and adherence with topical glaucoma therapy.

Authors:  Beth L Nordstrom; David S Friedman; Essy Mozaffari; Harry A Quigley; Alexander M Walker
Journal:  Am J Ophthalmol       Date:  2005-10       Impact factor: 5.258

Review 7.  Compliance and persistency in glaucoma follow-up treatment.

Authors:  Gail F Schwartz
Journal:  Curr Opin Ophthalmol       Date:  2005-04       Impact factor: 3.761

8.  Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS).

Authors:  David S Friedman; Harry A Quigley; Laurie Gelb; Jason Tan; Jay Margolis; Sonali N Shah; Elizabeth E Kim; Thom Zimmerman; Steven R Hahn
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-11       Impact factor: 4.799

Review 9.  [Compliance and persistence].

Authors:  M Detry-Morel
Journal:  J Fr Ophtalmol       Date:  2006-02       Impact factor: 0.818

10.  Compliance barriers in glaucoma: a systematic classification.

Authors:  James C Tsai; Cori A McClure; Sarah E Ramos; David G Schlundt; James W Pichert
Journal:  J Glaucoma       Date:  2003-10       Impact factor: 2.503

View more
  17 in total

1.  Release of Moxifloxacin From Corneal Collagen Shields.

Authors:  Siwei Zhou; Kristin M Hunt; Arman S Grewal; Kimberly M Brothers; Deepinder K Dhaliwal; Robert M Q Shanks
Journal:  Eye Contact Lens       Date:  2018-11       Impact factor: 2.018

2.  Pharmacokinetics and efficacy of Bioerodible Dexamethasone implant in Concanavalin A-induced uveitic cataract rabbit model.

Authors:  Srinivas Rao Chennamaneni; Austin Bohner; Ashlie Bernhisel; Balamurali K Ambati
Journal:  Pharm Res       Date:  2014-06-20       Impact factor: 4.200

3.  Assessing medication adherence: options to consider.

Authors:  Audrey Lehmann; Parisa Aslani; Rana Ahmed; Jennifer Celio; Aurelie Gauchet; Pierrick Bedouch; Olivier Bugnon; Benoît Allenet; Marie Paule Schneider
Journal:  Int J Clin Pharm       Date:  2013-10-29

4.  Dexamethasone Drug Eluting Nanowafers Control Inflammation in Alkali-Burned Corneas Associated With Dry Eye.

Authors:  Fang Bian; Crystal S Shin; Changjun Wang; Stephen C Pflugfelder; Ghanashyam Acharya; Cintia S De Paiva
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-06-01       Impact factor: 4.799

Review 5.  Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy.

Authors:  Tirth J Shah; Mandi D Conway; Gholam A Peyman
Journal:  Clin Ophthalmol       Date:  2018-11-01

6.  Optimization of cataract surgery follow-up: A standard set of questions can predict unexpected management changes at postoperative week one.

Authors:  Giannis A Moustafa; Durga S Borkar; Sheila Borboli-Gerogiannis; Scott H Greenstein; Alice C Lorch; Ryan A Vasan; Carolyn E Kloek
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

Review 7.  Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy.

Authors:  Cassandra C Brooks; Sayena Jabbehdari; Preeya K Gupta
Journal:  Clin Ophthalmol       Date:  2020-01-13

Review 8.  Clinical outcomes after injection of a compounded pharmaceutical for prophylaxis after cataract surgery: a large-scale review.

Authors:  Sydney L Tyson; Robert Bailey; Janika S Roman; Tingting Zhan; Lisa A Hark; Julia A Haller
Journal:  Curr Opin Ophthalmol       Date:  2017-01       Impact factor: 3.761

Review 9.  Investigation of medication adherence and reasons for poor adherence in patients on long-term glaucoma treatment regimes.

Authors:  Julie F McClelland; Lynne Bodle; Julie-Anne Little
Journal:  Patient Prefer Adherence       Date:  2019-08-12       Impact factor: 2.711

10.  Efficacy and safety of dropless cataract surgery.

Authors:  Narayan Bardoloi; Sandip Sarkar; Ashu Pilania; Himangshu Das
Journal:  Indian J Ophthalmol       Date:  2020-06       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.